CallDigest
Subscribe — $9/mo
Biotech & Pharma Intelligence — Every Monday

Every biotech catalyst. Every week. Before the market moves.

The only weekly digest built exclusively for biotech & pharma investors. FDA milestones, trial readouts, pipeline updates — scored and ranked so you know exactly where to focus.

Subscribe — $9/monthSee a sample issue ↓

Trusted by biotech investors tracking VRTX, MRNA, BIIB, REGN, LLY and 200+ more

VRTX ◆MRNA ◆BIIB ◆LLY ◆REGN ◆GILD ◆AMGN ◆ABBV ◆ALNY ◆BMRN ◆INCY ◆SGEN ◆HZNP ◆RARE ◆FOLD ◆SRPT ◆IONS ◆RETA ◆VRTX ◆MRNA ◆BIIB ◆LLY ◆REGN ◆GILD ◆AMGN ◆ABBV ◆ALNY ◆BMRN ◆INCY ◆SGEN ◆HZNP ◆RARE ◆FOLD ◆SRPT ◆IONS ◆RETA ◆VRTX ◆MRNA ◆BIIB ◆LLY ◆REGN ◆GILD ◆AMGN ◆ABBV ◆ALNY ◆BMRN ◆INCY ◆SGEN ◆HZNP ◆RARE ◆FOLD ◆SRPT ◆IONS ◆RETA ◆

How It Works

Three steps. Five minutes. Every Monday.

01

We collect

Every biotech/pharma earnings call transcript pulled from SEC EDGAR automatically each week

02

We score

Each call is analyzed by AI — risk, upside, and catalyst type extracted and scored 0–10

03

You decide

Ranked digest delivered Monday 8am UTC. Highest-interest calls first. 5-minute read.

Sample Digest

This week's digest — ranked by interest score

①

Vertex Pharmaceuticals

VRTX
🧬 FDA📊 Trial Data
  • 1NDA filing accepted for non-opioid pain drug — first in class with breakthrough designation intact.
  • 2Phase 3 trial meets primary endpoint with statistically significant pain reduction vs. oxycodone.
  • 3FY guidance raised +12%; management cites manufacturing readiness ahead of projected PDUFA date.
⚠️ Risk
2/10
🚀 Upside
9/10
⭐ Interest Score: 6.8⭐⭐⭐⭐⭐ Very High
②

Moderna

MRNA
📊 Trial Data💰 New Investor
  • 1mRNA-1283 next-gen COVID booster Phase 3 interim data positive — superior immunogenicity vs. current bivalent.
  • 2Manufacturing partnership announced — €800M upfront from European strategic partner, de-risking capex.
  • 3Cash runway extended to 24 months; no dilutive financing expected through pipeline milestones.
⚠️ Risk
4/10
🚀 Upside
7/10
⭐ Interest Score: 5.8⭐⭐⭐⭐☆ High
③

Biogen

BIIB
📈 Guidance🔬 Pipeline
  • 1Leqembi sales miss consensus by 18%; management cites reimbursement friction in key US markets.
  • 2FY revenue guidance lowered — Q3 now expected at $2.3B vs. $2.7B consensus.
  • 3Phase 2 pipeline candidate discontinued after interim futility analysis.
⚠️ Risk
7/10
🚀 Upside
3/10
⭐ Interest Score: 2.8⭐⭐☆☆☆ Low

+ 38 more biotech & pharma companies in this week's digest

Pricing

One plan. Full access. Cancel anytime.

Weekly Intelligence

$9/ month

or $89/year (save 17%)

  • Full weekly digest every Monday
  • All biotech & pharma earnings calls covered
  • Risk / Upside / Interest scores for every call
  • Catalyst tags: FDA, Trial Data, Pipeline, Guidance, New Investors
  • Ranked leaderboard — highest interest first
  • Cancel anytime
Start Subscribing

Powered by SEC EDGAR data. No conflicts of interest. No sponsored content.